Monday, January 27, 2020
Home Innovation That Matters

Innovation That Matters

Amicus Therapeutics: A Patient-First Approach to Treating Rare Diseases

Rare diseases have long posed a dual challenge. First, since there are relatively few patients by definition, they are not the highest priority for most drug makers. Second, many of them have proven quite difficult to effectively treat, let alone cure. The passage of the...

TDI Serves as a Bridge Between Academia and Industry, Leveraging All It Needs for Innovation

By Rich Soll, Senior Advisor, Strategic Initiatives, WuXi AppTec (@richsollwx) and WuXi AppTec Content Team The translation of academic discoveries into therapeutic products remains an issue despite passage of the Bayh-Dole Act (or Patent and Trademark Law Amendments...

SOTIO Arms Dendritic Cells for Immunotherapy Against Cancer

SOTIO has developed a method to generate autologous dendritic cells that express multiple tumor antigens on their surfaces to awaken oncology patients’ immune systems to attack the cancer. Radek Spisek, Ph.D., the company’s Global CEO, observed that cancer cells express many different...

Refuge Biotechnologies: Developing “Smart Cells” to Fight Cancer Inside the Human Body

Cell therapy is an emerging treatment with great potential because, unlike small molecules, cells are dynamic. They can migrate, proliferate, differentiate, and respond to their environment both in vitro and in vivo. Cell therapy company Refuge Biotechnologies, based in Menlo Park,...

RAPT Therapeutics Sees “Charged” Lung Cancer Tumors as Inviting Targets for Lead Drug FLX475

Lung cancer remains a stubborn disease to treat. Even cutting-edge immuno-therapies have had limited success. Brian Wong, CEO of South San Francisco-based RAPT Therapeutics, believes that the company’s lead drug, FLX475, has potential to overcome the scientific challenges in treating this disease.

SUBSCRIBE TO OUR NEWSLETTER

SPOTLIGHT

STAY CONNECTED

Twitter LinkedIn 

WUXI NEWS

WuXi Advanced Therapies Launches New World-Class AAV Vector Suspension Platform

New AAV Vector Suspension platform complements integrated capabilities – enabling cell and gene therapies to be developed, manufactured, and released faster and with greater...